May 12, 2022 -- PrecisionLife is joining forces with Sano Genetics to better understand the long-term effects of the coronavirus (long COVID). PrecisionLife’s proprietary combinatorial analytics platform will identify risk factors and potential drug targets by analyzing Sano Genetics’ data from 3,000 U.K. adults suffering from long COVID symptoms.
In particular, the new study seeks to determine why some people, even those with mild original COVID infections, are at risk of developing debilitating long COVID symptoms. The researchers also aim to discover novel drug targets and drug repositioning candidates with associated patient stratification biomarkers that could lead to new treatments for long COVID sufferers.
The partnership builds on support Sano Genetics received last year from the U.K. government funding body Innovate U.K. to anonymously gather genomic DNA data and patient-reported outcomes from 3,000 U.K. adults suffering from long COVID symptoms.
Copyright © 2022 scienceboard.net